Craif Launches Breast Cancer Test from “miSignal®️” Series Which Enables Early-stage Cancer Detection Using Urinary miRNA

 Craif Inc. (Location: Bunkyo-ku Tokyo, CEO: Ryuichi Onose, hereinafter referred to as “Craif”) will start offering Breast cancer test from 12th September 2022 through medical institutions as part of the “miSignal®️” series, a cancer risk screening test for early-stage cancer detection using urinary microRNA (hereinafter referred to as “miRNA”).  With this new product launch, miSignal®️ will be updated to a cancer test which can assess the risk of 2 cancer types (breast, and ovary) at once.

■ Background of this Launch 
 The number of new cases in Japan is 94,519(*) per year, and the mortality rate (per 100,000 population) is 12.1(*) for breast cancer. Although appropriate tests have been established for breast cancer (mammography), medical examination rate is not that high for this test since many people are not comfortable with painful tests or do not have time to go for checkups due to their busy schedules. Although recent medical advances have improved treatment outcomes, the 5-year relative survival rates by clinical progression are still 99.3% for localized and 6.4% for distant metastasis.
 Regardless of many medical advances made for breast cancer drugs and treatment, early detection and treatment is essential to fundamentally improve the prognosis. By developing and providing a painless and  straightforward urinary test useful to detect early-stage cancer, Craif will contribute to improve the prognosis of cancers.

(*) National Cancer Center Cancer Information Service, “Cancer Statistics” (National Cancer Registry)